Quick Answer
ZyVersa Therapeutics, Inc. reported Total Assets of $347.9 thousand for the year ending 2025.
- ZyVersa Therapeutics, Inc. showed a decrease of -98.3% in Total Assets from 2024 to 2025.
- This data is from ZyVersa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2021: $77.14 million | Q1 2022: $79.67 million | Q2 2022: $79.23 million | Q3 2022: $79.40 million | Q1 2023: $114.95 million | Q2 2023: $31.99 million | Q3 2023: $32.85 million | Q1 2024: $21.65 million | Q2 2024: $19.47 million | Q3 2024: $19.42 million | Q1 2025: $20.99 million | Q2 2025: $19.64 million | Q3 2025: $1.04 million.
- Over the full 5 years of available data (2021 to 2025), ZyVersa Therapeutics, Inc.'s Total Assets has declined by 99.5%.
- Historical annual values: Fiscal year 2025: $347.9 thousand | Fiscal year 2024: $20.60 million | Fiscal year 2023: $22.11 million | Fiscal year 2022: $118.51 million | Fiscal year 2021: $77.14 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: